Navigation Links
NeuroDerm Announces Positive Results of a Phase II Study of ND0611 Dermal Patch in Patients with Parkinson's Disease
Date:11/9/2011

NESS ZIONA, Israel, November 9, 2011 /PRNewswire/ --

NeuroDerm, Ltd. announced today the results of a Phase I/II safety and pharmacokinetic trial of ND0611, administered as an adjunct therapy to Sinemet®, Sinemet® CR or Stalevo®, in patients with advanced Parkinson's disease. ND0611 is a proprietary carbidopa liquid formula administered sub-cutaneously via a dermal patch to increase the bioavailability and efficacy of orally- administered levodopa. Results of this study support the continued development of ND0611 for the treatment of Parkinson's disease.

This double-blind, randomized, six-way crossover study met all of its primary and secondary endpoints. The analysis showed that ND0611, when compared with placebo, showed meaningful, highly statistically significant improvement in all of the pharmacokinetic (PK) endpoints when administered with three most common oral levodopa therapies (immediate-release Sinemet®,  Sinemet®-CR, and Stalevo®). The primary and secondary PK endpoints included levodopa half-life, the duration of levodopa concentration in excess of a threshold of 1000ng/ml in plasma, the area-under-the-concentration-time-curve and levodopa trough levels. The full results of this study will be presented at a future scientific meeting.

The most common adverse events across all treatment arms, including placebo, were vertigo, nausea, asthenia, back pain, myalgia, pain in extremity, headache and erythema. There were no clinically relevant effects seen in laboratory measured or vital signs.

"This first trial in patients of ND0611 hit all of its endpoints and was a complete success. ND0611 is an innovative treatment for PD and this important milestone justifies ND0611's further clinical and regulatory development," said Sheila Oren, MD, VP Clinical and Regulatory Affairs at NeuroDerm.

'/>"/>
SOURCE NeuroDerm Ltd
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. NeuroDerm Initiates Phase 2 Study of ND0801 in Patients with ADD/ADHD
2. NeuroDerm Successfully Completes Enrollment and Dosing in a Phase 1 Clinical Study of ND0611 Dermal Patch for Parkinsons Disease
3. China Sky One Medical Announces Third Quarter 2011 Results
4. China Information Technology, Inc. Announces Third Quarter 2011 Results
5. Uroplasty Announces Issuance of New Apparatus Patent for the Urgent® PC Neuromodulation System Stimulator
6. Micell Technologies Announces Positive Preliminary Data from DESSOLVE I Study of MiStent® Sirolimus Drug Eluting Coronary Stent System
7. K-V Pharmaceutical Announces Updated Makena® Performance Metrics
8. MedBox Announces Ticker Symbol Change
9. SMT Research & Development, Ltd. Names Shuki Porath as Vice President and General Manager, Announces TCT Presence
10. ECRI Institute Announces its Top 10 Health Technology Hazards for 2012
11. Echo Therapeutics Announces Third Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... JACKSONVILLE, Fla. , Aug. 28, 2015  With ... reaching deadlier heights, Jacksonville ... Philip Hemphill is helping to explain why ... Fentanyl is approximately 40 to 50 times more potent ... by recreational users as heroin, the risk of death ...
(Date:8/28/2015)... , Aug. 28, 2015  CytomX Therapeutics, Inc., a ... cancer, today announced the filing of a registration statement ... Commission (SEC) relating to a proposed initial public offering ... be offered and the price range for the offering ... its common stock under the symbol "CTMX" on the ...
(Date:8/28/2015)... 28, 2015 Research ... addition of the "Investigation Report on China,s ... Originally discovered by Welfide (Mitsubishi Tanabe ... Ltd) as an inflammatory drug, pranoprofen was later ... Ltd under the trade name of pranopulin for ...
Breaking Medicine Technology:Lakeview Health's Dr. Philip Hemphill Explains Why Heroin Addicts Are Now Dying of Fentanyl Overdoses 2CytomX Files Registration Statement for Proposed Initial Public Offering 2Investigation Report on China's Pranoprofen Market, 2010-2019 2
... Calif., Feb. 28, 2011 Varian Medical Systems, Inc. (NYSE: ... into a new agreement with Bank of America N.A. to ... share repurchase program.   Under the accelerated repurchase ... N.A. and receive approximately 3.5 million shares, or 85% of ...
... 2011 S*BIO Pte Ltd today announced that its ... (PK/PD) properties leading to significant anti-tumor efficacy in rapamycin-sensitive ... in vitro data on SB2343 were presented ... on Targeting PI3K/mTOR Signaling in Cancer held in San ...
Cached Medicine Technology:Varian Medical Systems Announces New $280 Million Accelerated Stock Repurchase 2Varian Medical Systems Announces New $280 Million Accelerated Stock Repurchase 3S*BIO's Novel Dual mTOR/PI3 Kinase Inhibitor SB2343 Demonstrates Excellent PK/PD Properties Leading to Significant Anti-Tumor Efficacy in Xenograft Models 2S*BIO's Novel Dual mTOR/PI3 Kinase Inhibitor SB2343 Demonstrates Excellent PK/PD Properties Leading to Significant Anti-Tumor Efficacy in Xenograft Models 3
(Date:8/29/2015)... ... August 29, 2015 , ... ... localized area with stretching, soft tissue manipulation. Platelet rich plasma injections also have ... through research to improve treatment outcomes. This localized treatment seems to address ...
(Date:8/28/2015)... Madre, CA (PRWEB) , ... August 28, 2015 ... ... solutions to wound center management, Decatur County Memorial Hospital recently transitioned management companies ... model of Wound Center Management for their outpatient wound center. , Transitioning ...
(Date:8/28/2015)... CA (PRWEB) , ... August 28, 2015 , ... An ... journey that local pizza maker Paul LaRocco has gone through to open a pizzeria ... approval and permitting process tends to take several months, but the current process, having ...
(Date:8/28/2015)... ... ... As reported by Medical Daily on August 22 , Cellfina, a non-invasive ... two years, the longest of any cellulite reduction system currently on the market. ... solution for their cellulite, according to Dr. Robert Weiss, director of the premier MD ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... ... 20 grams of high grade protein with zero fat, carbs, sugar, gluten, lactose ... been named a finalist for the 2015 SupplySide CPG Editor’s Choice Awards. , ...
Breaking Medicine News(10 mins):Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 4Health News:Article on Building Approval Process for LA Business Highlights the Need for a Bridge Between Businesses and City Officials, says Fire Protection Group Inc. 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 2Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 3
... ... technology for sales assessment testing helps employers customize a sales ability test for Customer ... 10 free sales ability tests , ... (PRWEB) May 13, 2010 -- Good sales people and good customer ...
... 13, 2010) -- A national summit of medical professionals ... of consensus scan techniques as a way of addressing ... common medical imaging procedure that uses X-rays to show ... together some of the world,s leading experts in CT ...
... Michigan survey, most said they,d try to get to ER on ... aren,t familiar with the symptoms of a stroke and most who ... stroke occurred, a new survey finds. , "If you know the ... them, that doesn,t do you much good," said study author Chris ...
... ... Diversified’s Information Lifecycle Solutions in the Financial, Insurance & Healthcare Industries, , ... Scranton, Pa. ... of document and information lifecycle solutions, announced today that it has formed a ...
... new study led by researchers from Mayo Clinic in ... patients with non-Hodgkin,s lymphoma who smoked, consumed alcohol or ... survival, compared to patients who did not have these ... and demographic factors, and also when considering only deaths ...
... for males tying the knot with younger females, study found , ... to nine years their junior could be upping their odds of ... significantly younger guy raises a woman,s risk of death by 20 ... of Demography . , Not that marrying much older men ...
Cached Medicine News:Health News:Top Sales Ability Test and Sales Assessment Test Does Customer Service Skills Assessment Testing Too 2Health News:Top Sales Ability Test and Sales Assessment Test Does Customer Service Skills Assessment Testing Too 3Health News:Top Sales Ability Test and Sales Assessment Test Does Customer Service Skills Assessment Testing Too 4Health News:Symposium focuses on patient safety in CT scanning 2Health News:Symposium focuses on patient safety in CT scanning 3Health News:Too Many Wouldn't Call 911 If Stroke Hit 2Health News:Too Many Wouldn't Call 911 If Stroke Hit 3Health News:Diversified Information Technologies and Sanava, Inc. Form Strategic Alliance 2Health News:Diversified Information Technologies and Sanava, Inc. Form Strategic Alliance 3Health News:Diversified Information Technologies and Sanava, Inc. Form Strategic Alliance 4Health News:Lifestyle factors significantly impact survival of non-Hodgkin's lymphoma patients, study finds 2Health News:Lifestyle factors significantly impact survival of non-Hodgkin's lymphoma patients, study finds 3Health News:Lifestyle factors significantly impact survival of non-Hodgkin's lymphoma patients, study finds 4Health News:Women Who Marry Younger Men May Die Earlier 2
... x 7.5 x 80 mm. Storz ... line designed by Harvey A. Lincoff, ... closed cell sponge which is non-toxic ... rounded edges to minimize scleral intrusion. ...
... 7.5 x 80 mm. Storz offers ... designed by Harvey A. Lincoff, M.D. ... cell sponge which is non-toxic and ... edges to minimize scleral intrusion. These ...
Thin silicone pad implant. Indications: For closing scleral ruptures. Overall length: 7.8 mm....
... Size: 5.0 x 2.5 x 80 mm. Half ... by Harvey A. Lincoff, M.D. has been modified ... design. The material is a closed cell sponge ... with rounded edges to minimize scleral intrusion. These ...
Medicine Products: